Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$3.31
▼ $0.08 (-2.4%)
Market data updated: 09/27 04:57 AM
Fundamentals updated: 09/27/2026
News analyzed: 09/27/2026
Market Cap
$271.57M
Day Range
$3.27 - $3.46
52-Week Range
$3.27 - $10.99
Beta
—
Next Earnings
09.11.2026
Support
$3.27
Resistance
$5.41
LXEO is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-49.1% (1Y)
Strengths: 6/28 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 39.8%
Growth
Biggest negative driver
Operating margin
Operating margin: -9309.2% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 3 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 3
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
38
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
today · $3.31
Evidence: Panic-selling score jumped from 10 to 60 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
46
Quality
47
Value
50
Momentum
10
Risk
46
Sentiment
68
Fundamental
34
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Lexeo Therapeutics has centered on its clinical and regulatory progress in gene therapy, particularly for Friedreich’s ataxia and PKP2-related arrhythmogenic cardiomyopathy. The company received FDA’s RMAT designation for LX2020 in August 2026, signaling accelerated development potential. Earlier, Lexeo published Phase I/II data for LX2006 in *JAMA Cardiology*, while finalizing its registrational trial design for the same therapy. Financial reports highlighted increased quarterly losses in Q2 2026, though analyst commentary continues to emphasize its potential as a high-growth biotech stock.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Lexeo Therapeutics, Inc.. News trend score: 68. Reason: 6 of the last 19 articles are positive, versus 3 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
50
🎯 Conviction (vs. Emotion)
49
Psychology
76
Fundamentals
34
Technical
10
Valuation
50
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price (3M)
-30%
Market Narrative
40
Fundamental Reality
49
Narrative Gap
-9
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
LXEO’s psychology score (13) reflects a *cautious, non-emotional* market stance, with no dominant bias. The data suggests traders are neither chasing gains (FOMO) nor fleeing (panic), but rather exhibiting *detached, low-volatility behavior*—consistent with neutral sentiment and modest momentum. The narrative gap (-11) hints at a slight disconnect between market expectations and fundamentals, but no clear behavioral trigger emerges. The key question: *Is this calmness a pause or a sign of broader disinterest?*
Updated: 09/05/2026, 10:41 PM
👥 What the crowd believes
"Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020"
"Phase I/II data for LX2006 in Friedreich Ataxia (article 8) | Registrational trial design for LX2006 (article 10) | Study design for Friedreich Ataxia gene therapy (article 9) | Publication of Phase I/II data (article 8)"
"Q2 EPS $(0.30) Misses $(0.28) Estimate (article 3) | 50% increase over prior losses (article 3)"
"Participate in upcoming investor conferences (article 1) | RBC Capital Markets Global Healthcare Conference (article 11)"
🧠 Market Brain events driving this
📈 3D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Benjamin Graham — 100/100
🔴 Weakest match
Philip Fisher — 9/100
🗣️ Why do they disagree?
This stock sparks a sharp divide between value-oriented and defensive investors, who see strong potential, and those wary of risk or market timing. Benjamin Graham and Walter Bagehot both rate it highly—Graham’s Defensive Investor finds it attractive due to its fundamentals, while Bagehot praises its liquidity as a credit squeeze buffer. However, Enterprising Graham and Howard Marks temper enthusiasm, with Marks warning that expectations may already be priced in, while the mid-cycle signals from Nelson and Marks’ cycle analysis suggest it’s neither a screaming buy nor a sell. Meanwhile, risk-averse voices like Loeb, Schwager, and Livermore dismiss it outright, with Loeb flagging its risk profile and Livermore’s trend-following rules rejecting it entirely. The contrast highlights how defensive, liquidity-focused strategies clash with trend- and volatility-sensitive approaches, leaving little consensus beyond cautious optimism from a few.
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 100
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 100
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 91
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 91
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 82
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 79
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 78
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 69
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 53
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 50
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 39
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 31
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 22
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 18
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 9
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Based on the last 287 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 10 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-9309.2%
Net Margin
-9120.0%
EBITDA Margin
—
ROE
-83.9%
ROA
-66.7%
ROIC
—
EPS
-$1.86
Cash
$63.00M
Total Debt
—
Current Ratio
11.21
Debt/Equity
0.00
How is Fair Value calculated? →
Current Price
$3.31
Estimated Fair Value (DCF)
-$34.41
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
⚠️ Extreme
Model output is extreme — likely a data/model limitation for this stock, not a reliable fair-value read.
Year 1 Growth Rate
10.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 10.0% | $-108.85M | $-99.87M |
| 2 | 8.1% | $-117.70M | $-99.06M |
| 3 | 6.3% | $-125.05M | $-96.56M |
| 4 | 4.4% | $-130.53M | $-92.47M |
| 5 | 2.5% | $-133.79M | $-86.95M |
Base FCF (last actual year)
$-98.96M
Terminal Value
$-2.11B
Present Value of Terminal Value
$-1.37B
Enterprise Value
$-1.85B
Net Debt
$0
Equity Value
$-1.85B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$3.38
Tangible Book Value per Share (Tangible NAV)
$2.92
Sentiment based on basic keywords (not AI) — 6 positive, 10 neutral, 3 negative out of the last 19 articles.
Yahoo · 23.9.2026
Yahoo · 23.9.2026
SeekingAlpha · 22.9.2026
SeekingAlpha · 22.9.2026
Yahoo · 22.9.2026
Benzinga · 22.9.2026
Yahoo · 2.9.2026
GlobeNewswire · 2.9.2026
GlobeNewswire · 12.8.2026
Benzinga · 12.8.2026
GlobeNewswire · 5.8.2026
SeekingAlpha · 27.7.2026
Insider Monkey · 15.7.2026
Insider Monkey · 2.7.2026
GlobeNewswire · 17.6.2026
MT Newswires · 15.6.2026
GlobeNewswire · 15.6.2026
GlobeNewswire · 19.5.2026
GlobeNewswire · 11.5.2026
Lexeo Therapeutics, Inc. (LXEO) currently has a StockIQ AI score of 38/100, rated "Weak". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
LXEO currently scores 38/100 (Weak) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
LXEO's technical score is 10/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 39.8%; Debt/equity: 0.00; Current ratio: 11.21.
Based on the real signals StockIQ computed: Operating margin: -9309.2% (negative); Net margin: -9120.0% (negative); Operating margin is eroding over time.
StockIQ has no recorded dividend payment history for LXEO.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 14 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Townsend Richard Nolan | Open Market Sale | 18.8.2026 | 374,472 | -3,345 | $4.95 |
| Otero Jose Manuel | Open Market Sale | 18.8.2026 | 136,178 | -1,304 | $4.96 |
| Tamayo Louis Edward | Open Market Sale | 18.8.2026 | 92,907 | -4,117 | $4.91 |
| Tamayo Louis Edward | Open Market Sale | 18.8.2026 | 4,117 | -4,117 | $4.91 |
| Otero Jose Manuel | Open Market Sale | 18.8.2026 | 1,304 | -1,304 | $4.96 |
| Townsend Richard Nolan | Open Market Sale | 18.8.2026 | 3,345 | -3,345 | $4.95 |
| Townsend Richard Nolan | Open Market Sale | 1.7.2026 | 25,947 | -25,947 | $4.48 |
| Tamayo Louis Edward | Open Market Sale | 1.7.2026 | 4,641 | -4,641 | $4.49 |
| Bhalla Narinder Pal | Open Market Sale | 1.7.2026 | 22,306 | -22,306 | $4.42 |
| Otero Jose Manuel | Open Market Sale | 1.7.2026 | 4,666 | -4,666 | $4.48 |
| Townsend Richard Nolan | Open Market Sale | 1.7.2026 | 377,817 | -25,947 | $4.48 |
| Otero Jose Manuel | Open Market Sale | 1.7.2026 | 137,482 | -4,666 | $4.48 |
| Tamayo Louis Edward | Open Market Sale | 1.7.2026 | 97,024 | -4,641 | $4.49 |
| Bhalla Narinder Pal | Open Market Sale | 1.7.2026 | 82,194 | -22,306 | $4.42 |
| Tamayo Louis Edward | Grant/Award from Employer | 29.6.2026 | 12,000 | +12,000 | — |
| Bhalla Narinder Pal | Grant/Award from Employer | 29.6.2026 | 55,000 | +55,000 | — |
| Otero Jose Manuel | Grant/Award from Employer | 29.6.2026 | 12,060 | +12,060 | — |
| Townsend Richard Nolan | Grant/Award from Employer | 29.6.2026 | 67,000 | +67,000 | — |
| Townsend Richard Nolan | Grant/Award from Employer | 29.6.2026 | 403,764 | +67,000 | — |
| Otero Jose Manuel | Grant/Award from Employer | 29.6.2026 | 142,148 | +12,060 | — |
| Tamayo Louis Edward | Grant/Award from Employer | 29.6.2026 | 101,665 | +12,000 | — |
| Bhalla Narinder Pal | Grant/Award from Employer | 29.6.2026 | 104,500 | +55,000 | — |
| Van Hauwermeiren Timothy | Grant/Award from Employer | 25.6.2026 | 35,000 | +35,000 | — |
| Tanguler Tolga | Grant/Award from Employer | 25.6.2026 | 35,000 | +35,000 | — |
| CHOLMONDELEY PAULA H | Grant/Award from Employer | 25.6.2026 | 35,000 | +35,000 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
20,627,916 shares short as of 2026-09-15 · vs. 20,485,477 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
48.8% of trading volume this week was short selling, vs. 46.0% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology